News >

Novel Approaches Push the Envelope in HER2+ Breast Cancer

Jessica Hergert
Published: Monday, Sep 09, 2019

Douglas K. Marks, MD, a medical oncologist at NYU Winthrop Hospital

Douglas K. Marks, MD

Developments in antibody-drug conjugates (ADCs), TKIs, and neoadjuvant interventions are improving outcomes for patients with early- and advanced-stage HER2-positive breast cancer, said Douglas K. Marks, MD, adding that investigational approaches could expand the treatment armamentarium even further.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication